BACKGROUND: Nigella sativa and its derivatives have been reported to have anti-inflammatory and bronchodilator effects, but the effects have been evaluated in only a few clinical studies. OBJECTIVES: To determine the effect of N sativa supplementation on @entity32 of the airways and limitation of airflow in partly controlled @entity565 @entity1 . DESIGN: Single-blind, placebo-controlled, randomized study. SETTING: Asthma and @entity566 clinic of a university hospital in eastern Saudi Arabia. @entity1 AND METHODS: @entity1 were divided into three groups. A control group (n=24) received the placebo, while @entity8768 and @entity3535 groups (n=26 each) received 1 and 2 g/day of N sativa, respectively, for 3 months along with maintenance inhaled therapy. MAIN OUTCOME MEASURE(S): Asthma control test (ACT) score, fractional exhaled @entity842 (FeNO), peak expiratory flow (PEF) variability and other pulmonary function tests, IgE, serum cytokines, and frequency of exacerbations. RESULTS: FEF25-75% and FEV1 (% predicted) increased significantly (P < .05) at both 6 and 12 weeks in the @entity3535 group. PEF variability significantly improved in both @entity8768 and @entity3535 groups at 6 and 12 weeks as compared with the controls (P < .05). FeNO and serum IgE decreased significantly after 12 weeks in both the @entity8768 and @entity3535 groups vs baseline (P < .05). Both doses of N sativa produced a significant increase in the serum @entity379 at 12 weeks vs baseline (P < .05) as well as a significant improvement in the ACT score at 6 and 12 weeks vs baseline (P < .001, < .01). Significantly fewer @entity1 had exacerbations in the @entity8768 group (P < .05). CONCLUSION: N sativa supplementation with inhaled maintenance therapy improves some measures of pulmonary function and @entity32 in partly controlled @entity565 . LIMITATIONS: No bronchoalveolar lavage or sputum samples taken for measurement of @entity565 markers. ISRCTN registry: ISRCTN48853858 DOI 10.1186/ISRCTN48853858.

Effect of Nigella sativa supplementation on lung function and inflammatory mediatorsin partly controlled XXXX : a randomized controlled trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity3535 :: ('57762', 'Gene') :: ['NS-2'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity379 :: ('3458', 'Gene') :: ['IFN-gamma'] @entity8768 :: ('10625', 'Gene') :: ['NS-1']
@entity565 :: (MESH:D001249,Disease) :: ['asthma']
